Back to Sites

Molepolole CRS

Site Number

12702

Address

Molepolole Prevention/Treatment Trials CRS
Scottish Livingstone Hospital
Gaborone-Molepolole Road
Molepolole,
Botswana

IMPAACT Members at this Site

Chenesani Bohule Clinical Research Assistant

Ayotunde Omoz-Oarhe Co-Investigator

Mpho Raesi CRS Coordinator

Akeem Salawu CRS Coordinator

Gaerolwe Masheto CRS Leader

Ayotunde Omoz-Oarhe CRS Leader

Ponego Ponatshego CRS Leader

Gaerolwe Masheto CTU Coordinator

Shahin Lockman CTU Principal Investigator

Joseph Makhema CTU Principal Investigator

Sue Welsch DAIDS PO

Farida Monggae Data Manager

Masego Rankowa Data Manager

Rasak Abdullahi Investigator

Unoda Chakalisa Investigator

Kenneth Maswabi Investigator

Sikhulile Moyo Laboratory Manager/Supervisor

Lesedi Tirelo Laboratory QA/QC Coordinator

Motswedi Anderson Laboratory Technician/Technologist

Rufaro Mangwarara Pharmacist

Tshepho Frank Pharmacy Supervisor

Urunduruka Munamava QA/QC Coordinator

Tumalano Sekoto Regulatory Coordinator

Tebogo Kakhu Staff

Tebogo Mokotedi Staff

Kelechi Nnajide Staff

Anthony Ogwu Staff

Studies at this Site

1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)

DAIDS Number

10779

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

P1026S: PK in Pregnancy

DAIDS Number

Therapeutics

Research Area

Treatment

Study Status

Closed to Follow Up

P1072: Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (RotaTeq™) in HIV-1 Infected and Uninfected Children Born to HIV-1 Infected Mothers

DAIDS Number

10638

Research Area

Complications & Comorbidities

Study Status

Concluded

P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants

DAIDS Number

10732

Research Area

Tuberculosis

P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir

DAIDS Number

11773

Research Area

Therapeutics

IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants

DAIDS Number

20735

Research Area

Cure and Immunotherapy

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2010: VESTED

DAIDS Number

30129

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

DAIDS Number

38506

Research Area

Brain and Mental Health

Study Status

Closed to Accrual

IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

DAIDS Number

38504

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

38609

Research Area

Therapeutics

Study Status

Enrolling